蛋白酶激活受体2 (PAR2) 的阻塞减轻了实验性自身免疫脑炎中的神经炎症
Rahil Eftekhari1, Benjamin W Ewanchuk1, Khalil S Rawji1
1Department of Physiology & Pharmacology (R.E., M.D.H.), Department of Medicine (R.E., M.D.H.), Department of Clinical Neurosciences (R.E., K.S.R., H.F.K.), Department of Biochemistry and Molecular Biology (B.W.E., R.M.Y.), Department of Comparative Biology and Experimental Medicine (B.W.E., R.M.Y.), and Department of Cell Biology and Anatomy (H.F.K.), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (R.E., F.N.).
在多发性硬化症模型中,抑制蛋白酶激活受体-2 (PAR2) 与抗剂一起降低了疾病严重程度. 这种方法抑制了免疫细胞的激活和透,为多发性硬化和神经炎症疾病提供了潜在的新疗法.
科学领域:
- 神经免疫学 神经免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白酶激活受体-2 (PAR2) 涉及炎症反应,并在多发性硬化症 (MS) 患者的中枢神经系统和实验性自身免疫脑炎 (EAE) 模型中升高.
- PAR2-null小鼠的EAE严重性显著降低,这表明PAR2在疾病发病过程中起着关键作用.
研究的目的:
- 研究抑制PAR2激活的治疗潜力,用于治疗多发性硬化症.
主要方法:
- 利用EAE小鼠模型来测试一种新型PAR2抗剂P2pal-18S的疗效.
- 评估了疾病的严重程度,脱髓化,免疫细胞透 (T细胞,巨细胞),粒细胞-巨细胞殖民地刺激因子 (GM-CSF) 生产,T细胞激活和巨细胞两极分化.
主要成果:
- P2pal-18S治疗显著减轻了EAE进展,减少了脱髓化,并减少了T细胞和巨细胞透到中枢神经系统.
- 反对剂还减少了GM-CSF的产生和T细胞激活在体外,并防止了巨细胞的两极分化.
结论:
- 在EAE模型中,PAR2在调节神经炎症方面发挥着关键作用.
- PAR2抗剂,如P2pal-18S,作为MS和其他神经炎症疾病的治疗药物表现有前途.
更多相关视频
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
